case_images: PMC5306975_01
case_images: (a) and (b): pretreatment: computed tomography of the facial sinuses. Presence of a solid voluminous mass extending throughout the right nasal cavity, measuring 3.8 x 3.1 x 5.1 cm along its longest axes. This mass is infiltrating the left nasal cavity, ethmoidal cells, and cribriform plate, causing erosion to the plate. (a) Coronal plane. (b) Axial plane. (c) and (d): midway through treatment: computed tomography of the facial sinuses. (c) Presence of a solid lesion affecting the ethmoidal cells, nasal cavity, and right sphenoid sinus, with the tumour extending as far as the floor of the sella turcica on the right, with erosion. No signs of pituitary involvement. Widening of the sphenoethmoidal recess due to infiltration of the tumour mass. Thickening of the mucosa occupying the maxillary sinuses bilaterally, principally on the right (coronal plane). (d) Lesion lodged in the right nasal cavity with deviation of the septum to the left (axial plane). (e) and (f): following treatment: computed tomography of the facial sinuses. Improvement of the sphenoid and right maxillary sinuses, with almost complete resolution of the lesions seen in previous exams. (e) Coronal plane. (f) Axial plane.
case_images: CRIONM2017-8201301.001.jpg
case_images: PMC5306975_01_CRIONM2017-8201301.001.jpg
case_images: fig1
case_images: Immunohistochemistry showed positivity for vimentin, S100, and HMB45 (human melanoma black 45), compatible with malignant melanoma (see Figures 1 and 2 and the following).
case_images: Immunohistochemical profile and histology of the lesion. (a) AE1 + AE3. (b) CD 138. (c) CK 8/18. (d) Desmin. (e) HMB 45. (f) S100 (x40):focal positivity. (g) Vimentin (x20):diffuse. (h) CD3. (i) CD20. (j) HE x10. (k) HE x20. (l) HE x40. Pleomorphic, polyhedral giant cells with large hyperchromatic nucleoli with a diffuse pattern.
case_images: CRIONM2017-8201301.002.jpg
case_images: PMC5306975_01_CRIONM2017-8201301.002.jpg
case_images: fig2
case_images: Immunohistochemistry showed positivity for vimentin, S100, and HMB45 (human melanoma black 45), compatible with malignant melanoma (see Figures 1 and 2 and the following).